Latest Breaking News On - Gastroenterology disease area leader - Page 1 : comparemela.com

TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn s Disease in a Phase 2 Study

TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn s Disease in a Phase 2 Study
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of cincinnatiSpring houseBritish columbiaCraig stoltzJan wehkampAnita afzaliJanssen scientific affairsJanssen research developmentCrohn colitis foundationNeither janssen research developmentDivision of digestive diseasesExchange commissionUniversity of cincinnati college medicinePrnewswire janssen pharmaceuticals incJanssen pharmaceutical companies of johnson

Jan Wehkamp, MD: Promising New Guselkumab Data From DDW 2023

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

United statesJan wehkampJanssen research developmentDisease weekVice presidentGastroenterology disease area leaderJanssen research

New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab).

Spring houseBritish columbiaUnited statesWaqqas afifJan wehkampColitis organizationDivision of experimental medicineCrohn colitis foundationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonDepartment of medicineUniversity health centreNone of the janssen pharmaceutical companiesDivision of gastroenterologyNational institutes of health

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with.

United statesSpring houseBritish columbiaCraig stoltzBurrillb crohnBrucee sandsJan wehkampAmerican college of gastroenterology annual meetingCrohn colitis foundationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican college of gastroenterologyJapan pharmaceuticalsNone of the janssen pharmaceutical companiesNational institutes of health

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and E

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and E
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSpring houseBritish columbiaCraig stoltzmobileBrucee sandsJan wehkampNone of the janssen pharmaceutical companiesCrohn colitis foundationSteering committeeColitis organisation onJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionIcahn school of medicine at mount sinaiCompanies of johnson